Talk:2-FMA
Dubious claim with bad reference
So, I noticed that this claim was made for both 2-fluorination & 4-fluorination, on the respective pages: "Studies demonstrate that 2-flourine amphetamine substitutions limit activity of the compound at the alpha-1 adrenergic receptor with an over 200-fold increased selectivity for A2 receptors over A1 receptors."
I decided to check the citation to see which one it supported, and realized that it was neither. The little bit about fluorinated norepinephrine is also pretty irrelevant in terms of SAR, so I think it was someone with a vested interest in selling these amphetamines attempting to justify the anecdotal effects / dose ceiling where applicable. I've removed the claim from the pages I noticed it in. Storm (talk) 04:57, 7 March 2017 (CET)
======
It's not that I don't believe it, but can anyone source the "emotionality suppression" effect for me? I find it a bit interesting that it would do that. And this can and ought to be subjective experience reports, since this is not something scientific literature will deal with, at least at this stage of scientific interest in 2-FMA. --Graatch (talk) 05:16, 14 August 2017 (CEST)
- Hello @Graatch:, thanks for weighing in. The "emotionality suppression" effect was included on grounds of the core pharmacology 2-FMA shares with amphetamine (and to a lesser extent, NDRIs like methylphenidate) as agents that promote synaptic concentrations of dopamine and norepinephrine. If you look up the effects reported for common ADHD stimulant medication like 'Adderall', 'Ritalin', 'Focalin', etc. you will see a number of people reporting this as a common effect.
- Interestingly, this seems to occur heterogeneously among the ADHD population, in which either amphetamine or MPH will cause this more or less depending on the person. The common factor between these reports is that while the initial stages of stimulant use correspond with increased mood and the enhancement of emotions (particularly positive ones that promote sociability), these reports appear to decrease among those who have been on the medication for an extended period and have presumably built tolerance to these aspects. A small sample of such can be found here: https://www.reddit.com/r/ADHD/comments/3wn9se/how_do_people_tolerate_the_emotional_blunting/ And more can be found if you browse various ADHD forums, or forums with threads on regular (if not necessarily abusive) stimulant use.
- Anecdotally, a number of trusted PW contributors who have experimented with this compound report that, at least past the initial stages of use, the net effect that 2-FMA has on emotions is, like amphetamine itself, one of suppressed emotions in return for increased ability to focus "robotically" on tasks that may otherwise be unable to be focused on.
- Interestingly, when you get the basic activity of 2-FMA as a norepinephrine and dopamine releaser, and then consider it in relation to 4-FA, which we do not list this effect under, and releases DA and NE as well as serotonin, you may get a better sense for what is going on, as it distinctly elicits the opposite effect of "enhanced emotionality" (in the entactogenic sense particularly). It is the same relationship you will find between regular amphetamine and MDMA, in terms of how one they differ in emotional effects.
Citation needed rollback?
I was wondering why these 3 effects are special among the others and need a specific citation since none of the others need it. According to the previous point on the talk page, effects were able to be added based off of the drug's similarity to amphetamine, surely abnormal heartbeat, and increased heartrate and blood pressure are basic enough effects of stimulants that they don't have to be specifically cited? How would you even go about sourcing an index effect especially for research chemicals? There aren't trip reports attached to every any of the listed effects let alone all of them and even then it would just be anecdotal claims since it's not part of a study or something. Pharmreduction (talk) 20:57, 13 August 2017 (PST)